CA2560167A1 - Statins for the treatment of ocular hypertension and glaucoma - Google Patents

Statins for the treatment of ocular hypertension and glaucoma Download PDF

Info

Publication number
CA2560167A1
CA2560167A1 CA002560167A CA2560167A CA2560167A1 CA 2560167 A1 CA2560167 A1 CA 2560167A1 CA 002560167 A CA002560167 A CA 002560167A CA 2560167 A CA2560167 A CA 2560167A CA 2560167 A1 CA2560167 A1 CA 2560167A1
Authority
CA
Canada
Prior art keywords
composition
hmg
coa reductase
patient
reductase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002560167A
Other languages
English (en)
French (fr)
Inventor
Mark R. Hellberg
Debra L. Fleenor
Allan Shepard
Iok-Hou Pang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2560167A1 publication Critical patent/CA2560167A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002560167A 2004-04-26 2005-04-25 Statins for the treatment of ocular hypertension and glaucoma Abandoned CA2560167A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56546904P 2004-04-26 2004-04-26
US60/565,469 2004-04-26
PCT/US2005/014255 WO2005105069A1 (en) 2004-04-26 2005-04-25 Statins for the treatment of ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
CA2560167A1 true CA2560167A1 (en) 2005-11-10

Family

ID=34966865

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002560167A Abandoned CA2560167A1 (en) 2004-04-26 2005-04-25 Statins for the treatment of ocular hypertension and glaucoma

Country Status (19)

Country Link
US (2) US20050239871A1 (enExample)
EP (1) EP1740164B1 (enExample)
JP (1) JP2007534699A (enExample)
KR (2) KR20110091600A (enExample)
CN (1) CN1946384B (enExample)
AT (1) ATE404189T1 (enExample)
AU (1) AU2005237543B2 (enExample)
BR (1) BRPI0510245A (enExample)
CA (1) CA2560167A1 (enExample)
CY (1) CY1108490T1 (enExample)
DE (1) DE602005008935D1 (enExample)
DK (1) DK1740164T3 (enExample)
ES (1) ES2311986T3 (enExample)
MX (1) MXPA06012225A (enExample)
PL (1) PL1740164T3 (enExample)
PT (1) PT1740164E (enExample)
SI (1) SI1740164T1 (enExample)
WO (1) WO2005105069A1 (enExample)
ZA (1) ZA200607988B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053683A1 (en) * 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
WO2007070866A2 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
PL2018153T3 (pl) 2006-04-26 2012-09-28 Rosemont Pharmaceuticals Ltd Ciekłe kompozycje doustne
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
ES2330184B1 (es) * 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
CN102093984B (zh) * 2010-11-23 2012-07-04 清华大学 一种杂合酶P450sca2-BMR及其编码基因与应用
CN104902892A (zh) 2012-02-02 2015-09-09 悉尼大学 泪液膜稳定性的改进
GB201611782D0 (en) * 2016-07-06 2016-08-17 Optibiotix Ltd Composition
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
WO2025147589A1 (en) * 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
FR2585708B1 (fr) * 1985-07-31 1989-07-07 Sanofi Sa Derives aminoalcools peptidiques inhibiteurs de la resine et des proteases acides, leur procede de preparation et leur application en therapeutique
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ES2213504T1 (es) * 1988-09-06 2004-09-01 Pfizer Health Ab Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
FR2647675B1 (fr) * 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
JPH04243835A (ja) * 1990-08-29 1992-08-31 Pfizer Inc 高眼圧症又は緑内障治療用薬剤組成物及び治療方法
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
EP1322306A2 (en) * 2000-09-19 2003-07-02 NovImmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US20030065020A1 (en) * 2001-07-13 2003-04-03 Catharine Gale Treatment of macular degeneration
US20030195167A1 (en) * 2002-04-15 2003-10-16 Kowa Co., Ltd. PTX3-gene expression inhibitor
JP2004149480A (ja) * 2002-10-31 2004-05-27 Saisentan Igaku Kenkyusho:Kk 経口又は経皮投与用の眼科疾患治療剤
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
CA2523808A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20060241122A1 (en) * 2003-05-30 2006-10-26 Lee Margaret S Combination therapy for the treatment of neoplasms
WO2005053683A1 (en) * 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders

Also Published As

Publication number Publication date
AU2005237543A1 (en) 2005-11-10
US20050239871A1 (en) 2005-10-27
SI1740164T1 (sl) 2009-02-28
EP1740164A1 (en) 2007-01-10
PT1740164E (pt) 2008-10-21
KR20110091600A (ko) 2011-08-11
CY1108490T1 (el) 2014-04-09
ATE404189T1 (de) 2008-08-15
KR20070007932A (ko) 2007-01-16
CN1946384A (zh) 2007-04-11
CN1946384B (zh) 2011-04-20
HK1102913A1 (en) 2007-12-07
WO2005105069A1 (en) 2005-11-10
US20110098314A1 (en) 2011-04-28
ZA200607988B (en) 2007-12-27
DK1740164T3 (da) 2008-11-10
PL1740164T3 (pl) 2009-01-30
JP2007534699A (ja) 2007-11-29
ES2311986T3 (es) 2009-02-16
BRPI0510245A (pt) 2007-10-23
DE602005008935D1 (de) 2008-09-25
KR101071192B1 (ko) 2011-10-10
AU2005237543B2 (en) 2011-02-10
EP1740164B1 (en) 2008-08-13
MXPA06012225A (es) 2007-01-31

Similar Documents

Publication Publication Date Title
US20110098314A1 (en) Statins for the treatment of ocular hypertension and glaucoma
WO2004103960A2 (en) Compounds and uses thereof
EP1510208A1 (en) Pharmaceutical composition comprising a combination of metformin and statin
US20150272944A1 (en) Novel triglyceride reducing agent
CA3134764A1 (en) Compositions and methods for use of cannabinoids for neuroprotection
US7772258B2 (en) Agent for treatment of allergic eye disease
US20040087597A1 (en) Preventives and remedies for complications of diabetes
US20100204249A1 (en) Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
KR20130137623A (ko) 림프 부종 예방 치료제
RU2266736C2 (ru) Способ и композиции для ингибирования артериосклероза
HK1102913B (en) Statins for the treatment of ocular hypertension and glaucoma
CA2492781A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocystein
US20080070938A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocysteine
US20040248972A1 (en) Compounds and uses thereof
AU2009327374A1 (en) Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase A2 (sPLA2) inhibitor or sPLA2 inhibitor combination therapies
EP1752145A1 (en) Therapeutic agent for hyperlipemia and therapeutic agent for diabetes
HK1111632B (en) Novel triglyceride reducing agent
CA2494801A1 (en) Medicinal composition containing hmg-coa reductase inhibitor
CA2434691A1 (en) Use of propentofylline to control intraocular pressure

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140415